Gubra A/S
39.26
EUR
-0.42
(-1.06%)
ISIN
DK0062266474
Return %
Stock
S&P 500
1Y
-30.08
14.20
3Y
216.10
81.12
5Y
- -
68.34
Capital Structure
DKK
•
in mil. unless spec.Working Capital
DKK
•
in mil. unless spec.Growth Rates
DKK
•
in mil. unless spec.Semi-annual Revenue
DKK
•
in mil. unless spec.Semi-annual Earnings Per Share
DKK
•
in mil. unless spec.Semi-annual Dividends Per Share
DKK
•
in mil. unless spec.Company Description
- CEO
- Markus Rohrwild
- Full Time Employees
- 269
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- Hørsholm Kongevej 11B Hørsholm CR Denmark 2970
- IPO Date
- Apr 4, 2023
- Website
- gubra.dk
- Similar Companies
- Business
- Gubra A/S (GUBRA.CO) is a Denmark-based biotechnology company that specializes in high-end preclinical contract research organization (CRO) services and peptide-based drug discovery focused on metabolic and fibrotic diseases; its operations span Europe, North America and other international markets from headquarters in Hørsholm, Denmark, where it was founded in 2008. The company delivers comprehensive preclinical research solutions including in vivo pharmacology, ex vivo assays, drug profiling, pharmacokinetics, biomarker assays, bioinformatics, next-generation sequencing (NGS), 2D and 3D histology with artificial intelligence pathology, stereology, and whole brain and organ imaging; these services target disease areas such as liver (MASH), obesity, kidney (DKD/CKD/PKD/AKI), diabetes, central nervous system (CNS), lung (IPF), and non-rodent studies in miniature pigs, serving pharmaceutical and biotechnology clients including 16 of the top 20 global pharmaceutical companies. Gubra organizes activities into two synergistic segments: CRO Services, which generates steady cash flow through specialized preclinical studies in translatable rodent and non-rodent models, and Discovery & Partnerships (D&P), which identifies and develops peptide-based drug candidates like amylin analogs and urocortin-2 (UCN2) programs for obesity for potential partnering with development milestone payments and royalties. Recent developments include a March 2025 license agreement with AbbVie granting global rights to develop GUB014295, a long-acting amylin analog for obesity treatment, providing a $350 million upfront payment and up to $1.875 billion in milestones; ongoing partnerships with Boehringer Ingelheim for obesity, Hemab ApS for bleeding disorders, and seven active collaborations overall; preparation for a first-in-human study of its UCN2 obesity program in early 2026; maintenance of full-year 2025 CRO growth guidance at 20% amid solid European demand; and evaluation of merger, acquisition, and pipeline expansion opportunities using AbbVie proceeds.